A Phase I Study of the Combination of Gemcitabine Plus Dasatinib in Patients With Refractory Solid Tumors With an Expanded Cohort in Advanced Pancreatic Cancer.
Phase of Trial: Phase I
Latest Information Update: 16 Sep 2014
At a glance
- Drugs Dasatinib; Gemcitabine
- Indications Pancreatic cancer; Solid tumours
- Focus Adverse reactions; Biomarker
- 22 Jun 2012 Additional lead trial investigator identified as reported by ClinicalTrials.gov.
- 22 Jun 2012 Actual patient number 30 added as reported by ClinicalTrials.gov.
- 22 Jun 2012 Planned End Date changed from 1 Jun 2011 to 1 May 2012 as reported by ClinicalTrials.gov.